BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children.

MLA

Kriván, Gergely, et al. “BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children.” Journal of Clinical Immunology, vol. 43, no. 3, Apr. 2023, pp. 557–67. EBSCOhost, https://doi.org/10.1007/s10875-022-01397-0.

APA

Kriván, G., Borte, M., Soler-Palacin, P., Church, J. A., Csurke, I., Harris, J. B., Lieberman, J. A., Melamed, I. R., Moy, J. N., Simon, R., Aigner, S., Lentze, S., & Staiger, C. (2023). BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children. Journal of Clinical Immunology, 43(3), 557–567. https://doi.org/10.1007/s10875-022-01397-0

Chicago

Kriván, Gergely, Michael Borte, Pere Soler-Palacin, Joseph A Church, Ildiko Csurke, James B Harris, Jay A Lieberman, et al. 2023. “BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children.” Journal of Clinical Immunology 43 (3): 557–67. doi:10.1007/s10875-022-01397-0.